ContextVision（CONTX）株式概要
ソフトウェア会社であるContextVision AB (publish)は、アジア、ヨーロッパ、アメリカにおいて、医療システム用の画像解析と画像処理を提供している。 詳細
CONTX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ContextVision AB (publ) 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | NOK 3.55 |
| 52週高値 | NOK 4.99 |
| 52週安値 | NOK 2.70 |
| ベータ | 0.22 |
| 1ヶ月の変化 | 1.72% |
| 3ヶ月変化 | 4.41% |
| 1年変化 | -27.70% |
| 3年間の変化 | -59.29% |
| 5年間の変化 | -80.95% |
| IPOからの変化 | -4.05% |
最新ニュース
ナラティブの更新 • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.ナラティブの更新 • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.ナラティブの更新 • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.ナラティブの更新 • Mar 11
CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.Recent updates
ナラティブの更新 • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.ナラティブの更新 • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.ナラティブの更新 • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.ナラティブの更新 • Mar 11
CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.ナラティブの更新 • Feb 24
CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside
Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.ナラティブの更新 • Feb 09
CONTX: Liver Diagnostics Study Progress Will Support Steady Long Term Outlook
Analysts have adjusted their price target for ContextVision to reflect a fair value of $4.00 and a future P/E of 11.34, citing updated assumptions around discount rates and profitability. What's in the News ContextVision started patient enrollment in its clinical development program for liver disease diagnostics at the University of Washington in Seattle, following Institutional Review Board approval and completion of technical setup (Key Developments).ナラティブの更新 • Jan 25
CONTX: Liver Study Progress And Buybacks Will Support Steady Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect small updates to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall outlook broadly unchanged. What's in the News ContextVision started the clinical phase of its liver disease diagnostics program at the University of Washington in Seattle, with the first patient first visit completed following Institutional Review Board approval and technical validation (Key Developments).ナラティブの更新 • Jan 10
CONTX: Share Buybacks And Stable Assumptions Will Support Steady Long Term Outlook
Analysts have slightly adjusted their price target on ContextVision, reflecting modest tweaks to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. They describe the move as a fine tuning of their outlook rather than a major shift in thesis.ナラティブの更新 • Dec 25
CONTX: Share Buybacks Will Support Per Share Metrics With Stable Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect modest improvements in long term fair value and profitability assumptions, now estimating the stock to be worth approximately SEK 4.00 per share versus about SEK 4.00 previously. What's in the News Completed a share buyback tranche, repurchasing 1,440,211 shares (equivalent to 1.86% of outstanding capital) between September 5 and September 30, 2025 (Key Developments) Total consideration for the completed buyback program amounted to NOK 6.42 million under the mandate announced on September 15, 2025 (Key Developments) The conclusion of this buyback tranche reduces the free float and may provide incremental support to per share metrics ahead of future results updates (Key Developments) Valuation Changes Fair Value Estimate is effectively unchanged at around SEK 4.00 per share, reflecting only immaterial rounding differences in the model.ナラティブの更新 • Dec 11
CONTX: Share Buybacks Will Support Capital Efficiency With Balanced Long Term Outlook
Analysts have raised their price target for ContextVision slightly, now valuing the shares at roughly SEK 4.00. This reflects modestly higher confidence in the companys long term earnings power, even as underlying model assumptions have changed only marginally.ナラティブの更新 • Nov 27
CONTX: Share Repurchase Program Will Drive Capital Efficiency And Future Upside
Analysts have adjusted their price target for ContextVision slightly upward to $4.00, citing marginal updates to the discount rate as well as modest changes in growth and profitability assumptions. What's in the News ContextVision completed the repurchase of 1,440,211 shares, representing 1.86% of shares, for NOK 6.42 million between September 5 and September 30, 2025.分析記事 • Nov 19
More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%
The ContextVision AB (publ) ( OB:CONTX ) share price has fared very poorly over the last month, falling by a...ナラティブの更新 • Nov 12
CONTX: Share Repurchase Program And Margin Outlook Will Shape Future Performance
Analysts have lowered their price target for ContextVision from $5.00 to $4.00, citing a modest decline in expected revenue growth and a slightly higher discount rate. This adjustment comes despite improved profit margin forecasts.分析記事 • Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...分析記事 • Sep 09
We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings
A lackluster earnings announcement from ContextVision AB (publ) ( OB:CONTX ) last week didn't sink the stock price...分析記事 • Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...ナラティブの更新 • Aug 09
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).分析記事 • May 09
This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts
One thing we could say about the covering analyst on ContextVision AB (publ) ( OB:CONTX ) - they aren't optimistic...分析記事 • Mar 04
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
The market for ContextVision AB (publ)'s ( OB:CONTX ) shares didn't move much after it posted weak earnings recently...
新しいナラティブ • Feb 26
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
Expansion into Asian markets and integration with new customers will boost revenues via enhanced customer base and market presence.分析記事 • Feb 25
Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%
ContextVision AB (publ) ( OB:CONTX ) shares have had a really impressive month, gaining 25% after a shaky period...分析記事 • Feb 15
Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not have the largest market cap around , it saw a significant share...分析記事 • Sep 02
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
Shareholders appeared unconcerned with ContextVision AB (publ)'s ( OB:CONTX ) lackluster earnings report last week. Our...分析記事 • Mar 11
ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
ContextVision AB (publ) ( OB:CONTX ) shares have had a horrible month, losing 26% after a relatively good period...分析記事 • Feb 22
ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear
The most recent earnings report from ContextVision AB (publ) ( OB:CONTX ) was disappointing for shareholders. However...分析記事 • Feb 18
ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 17% to kr7.50...分析記事 • Jan 26
Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)
With a price-to-earnings (or "P/E") ratio of 18.4x ContextVision AB (publ) ( OB:CONTX ) may be sending very bearish...分析記事 • Jun 22
When Should You Buy ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not be the most widely known stock at the moment, it saw a decent...株主還元
| CONTX | NO Healthcare Services | NO 市場 | |
|---|---|---|---|
| 7D | -3.5% | 3.6% | 3.2% |
| 1Y | -27.7% | -10.2% | 24.9% |
業界別リターン: CONTX過去 1 年間で-10.2 % の収益を上げたNorwegian Healthcare Services業界を下回りました。
リターン対市場: CONTXは、過去 1 年間で24.9 % のリターンを上げたNorwegian市場を下回りました。
価格変動
| CONTX volatility | |
|---|---|
| CONTX Average Weekly Movement | 7.6% |
| Healthcare Services Industry Average Movement | 6.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in NO Market | 12.4% |
| 10% least volatile stocks in NO Market | 3.3% |
安定した株価: CONTX 、 Norwegian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CONTXの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1989 | 43 | Gerald Potzsch | www.contextvision.se |
ソフトウェア会社であるContextVision AB (publish)は、アジア、ヨーロッパ、アメリカにおいて、医療システム向けの画像解析と画像処理を提供している。超音波の画質ソリューションを提供しており、2D画像補正のRivent、プレミアム2D画像補正製品のRivent Plus、3D超音波の画質を向上させるソリューションのRivent 3D、放射線科、循環器科、女性の健康、獣医学、ポイント・オブ・ケア・アプリケーションなど様々な分野の診断用のハンドヘルドデバイス用の2D画像補正のRivent MobileからなるRiventプラットフォームを提供している。また、散乱線補正機能を搭載し、画質を向上させながら放射線量の低減を可能にすることで、X線撮影を改善するAltumiraプラットフォーム（静的アプリケーション向けのAltumira、動的アプリケーション向けのAltumira Plusなど）も提供しています。さらに、各アプリケーション、シーケンスタイプ、プロトコルの要件に対応したGOPView MRI2Plus、導入プロジェクト、ソフトウェアアップデート、アップグレード、製品サポートサービスなどのMRI向け画質ソリューションを提供している。同社は、肝疾患MASLDのスクリーニングと病期分類のためのマルチパラメトリックバイオマーカーを特定するための医療画像データを収集するために、ワシントン大学医学部と戦略的臨床開発パートナーシップを結んでいる。ContextVision AB（publ）は1983年に設立され、スウェーデンのストックホルムに本社を置いている。
ContextVision AB (publ) 基礎のまとめ
| CONTX 基礎統計学 | |
|---|---|
| 時価総額 | NOK 264.69m |
| 収益（TTM） | NOK 4.67m |
| 売上高(TTM) | NOK 112.45m |
56.6x
PER（株価収益率2.4x
P/SレシオCONTX は割高か？
公正価値と評価分析を参照収益と収入
| CONTX 損益計算書（TTM） | |
|---|---|
| 収益 | SEK 113.49m |
| 売上原価 | SEK 64.90m |
| 売上総利益 | SEK 48.59m |
| その他の費用 | SEK 43.88m |
| 収益 | SEK 4.72m |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 27, 2026
| 一株当たり利益（EPS） | 0.063 |
| グロス・マージン | 42.82% |
| 純利益率 | 4.16% |
| 有利子負債／自己資本比率 | 0% |
CONTX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 15:08 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
ContextVision AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3
| アナリスト | 機関 |
|---|---|
| Juste Subataviciute | Norne Securities AS |
| Christian Lee | Pareto Securities |
| Klas Palin | Redeye |